Recent 8-K filings for PTN

• November 12, 2025, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Palatin closes $18.2M public offering, regains NYSE American listing compliance

  Closed upsized public offering of 2,795,384 shares/pre-funded warrants and warrants at combined $6.50, gross proceeds $18.2M.

• November 6, 2025, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 8.01item 9.01

  Palatin prices $15.8M public offering; NYSE American listing resumes Nov 12

  Priced upsized public offering of 2.43M shares at $6.50/unit; gross proceeds ~$15.8M.

• September 22, 2025, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Palatin earns €5.5M milestone payment from Boehringer Ingelheim in retinal disease collaboration

  Achieved research milestone in collaboration with Boehringer Ingelheim, triggering €5.5M ($6.5M) payment to Palatin.

• September 10, 2025, 7:59 PM ET other materiality 0.65 negative item 8.01

  Palatin begins OTCQB trading under PTNT after 1-for-50 reverse split; delisted from NYSE American

  NYSE American suspended trading and initiated delisting on May 7, 2025, due to low stock price.

• August 18, 2025, 7:59 PM ET other material materiality 0.75 positive item 1.01item 7.01item 9.01

  Palatin signs up to €280M collaboration with Boehringer for retinal disease therapies

  €2M upfront, up to €18M near-term milestones, up to €260M in regulatory/commercial milestones plus tiered royalties.

• August 11, 2025, 7:59 PM ET other material materiality 0.70 negative item 7.01

  Palatin Technologies to effect 1-for-50 reverse stock split on August 11, 2025

  Reverse split effective after market on August 11; split-adjusted trading on OTCQB begins August 12.

• August 8, 2025, 7:59 PM ET other materiality 0.65 neutral item 3.03item 5.03item 7.01item 9.01 ◈ Governance Changes

  Palatin Technologies announces 1-for-50 reverse stock split effective Aug 8, 2025

  Reverse stock split at 1-for-50 ratio effective 5:00 p.m. ET on August 8, 2025.

• July 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 5.07item 9.01

  Palatin shareholders approve reverse stock split (1:50-1:100) and increase shares for equity awards

  Reverse stock split (1:50-1:100) approved; 12.4M for, 8.2M against. Board to set exact ratio.

• July 9, 2025, 7:59 PM ET other material materiality 0.60 negative item 3.01item 9.01 ◈ Listing & Compliance Notices

  NYSE American Panel affirms delisting of Palatin Technologies; stock trades on OTCQB

  Panel unanimously affirmed delisting under Sections 1003(a) and 1003(f)(v) due to low selling price of common stock.

• June 13, 2025, 7:59 PM ET other material materiality 0.75 negative item 1.01item 5.03item 3.02item 9.01 ◈ Governance Changes

  Palatin Technologies delisted from NYSE American; raises $340K in insider private placement

  NYSE American commenced delisting proceedings; common stock suspended May 7, 2025. Now trades on OTCQB under PTNT.

• May 8, 2025, 7:59 PM ET other material materiality 0.75 negative item 1.01item 3.01item 8.01item 9.01 ◈ Listing & Compliance Notices

  Palatin Technologies delisted from NYSE American; reduced offering raises only $1.1M

  NYSE American suspended trading and commenced delisting proceedings due to low stock price; shares transitioned to OTC Pink under 'PTNT'.

• April 10, 2025, 7:59 PM ET regulatory materiality 0.85 negative item 3.01item 8.01item 9.01 ◈ Listing & Compliance Notices

  Palatin Technologies receives NYSE American delisting notice; intends to appeal

  NYSE Regulation determined to delist PTN for failure to comply with stockholders' equity requirements (Sections 1003(a)(i)-(iii)).

• March 31, 2025, 7:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Palatin reports positive Phase 2 topline results for UC drug PL8177 and obesity combo study

  UC Phase 2: Clinical remission 33% PL8177 vs 0% placebo; clinical response 78% vs 33% (p<0.005) after 8 weeks.

• February 10, 2025, 6:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 8.01item 9.01

  Palatin Technologies announces $4.7M equity offering at $1.00/share, private warrants

  Gross proceeds ~$4.7M from sale of 2.55M shares at $1.00/share and pre-funded warrants for 2.138M shares.

• December 16, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 7.01item 9.01

  Palatin receives ~$3.4M from warrant exercise; issues new Series C/D warrants

  Gross proceeds of ~$3.4M from exercise of 3,907,679 shares at amended price $0.875.

• November 14, 2024, 6:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Palatin Q1 net loss $7.8M; obesity focus with BMT-801 topline Q1 2025; strategic review for non-obesity assets

  Net loss $7.8M ($0.39/share) vs $5.2M a year ago; cash $2.4M at Sep 30, plus $2.5M deferred payment from Vyleesi sale received Nov 2024.

• October 7, 2024, 7:59 PM ET regulatory materiality 0.70 negative item 3.01item 8.01item 9.01

  Palatin receives NYSE American delisting notice for equity deficiency; cure period extended to April 2025

  NYSE American notified Palatin of non-compliance with Section 1003(a)(iii) requiring stockholders' equity of at least $6M after five consecutive years of losses.

• October 1, 2024, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Palatin reports FY2024 net loss $29.7M, cash $9.5M; outlines clinical milestones for obesity, DED, ED, UC

  Net loss for FY2024 $29.7M ($2.02 per share) vs $24.0M ($2.21) prior year; revenue declined as Vyleesi asset sold.

• June 21, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 7.01item 9.01

  Palatin Technologies raises ~$6.1M via warrant inducement with institutional investor

  Enters inducement letter; institutional investor exercises existing warrants for $6.1M gross proceeds.

• May 15, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Palatin Q3 net loss $8.4M; Phase 3 DED study meets pain endpoint, 7 of 11 secondary endpoints

  Phase 3 MELODY-1 for PL9643 in dry eye disease met co-primary pain endpoint (P<0.025) and 7 of 11 secondary endpoints at 12 weeks; rapid onset at 2 weeks.

• February 15, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Palatin Q2 FY2024 net loss $7.8M; Vyleesi sale closed; pipeline catalysts ahead

  Net loss of $7.8M ($0.56/share) vs net income of $2.7M ($0.25) in Q2 FY2023.

• February 1, 2024, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements

  Palatin closes $10M registered direct offering; details Vyleesi sale to Cosette with $12M upfront

  Registered direct offering closed Feb 1: 1,831,503 shares at $5.46, gross $10M, net proceeds ~$9.2M.

• December 20, 2023, 6:59 PM ET other material materiality 0.80 neutral item 1.01item 2.01item 8.01item 9.01 ◈ M&A Transactions◈ Material Agreements

  Palatin sells Vyleesi rights to Cosette for up to $171M; $12M upfront

  Up-front payment of $12M plus sales-based milestones up to $159M based on annual net sales of $15M to $200M.

• December 18, 2023, 6:59 PM ET regulatory materiality 0.70 negative item 3.01item 8.01item 9.01 ◈ Listing & Compliance Notices ×2

  NYSE American accepts Palatin's plan to regain listing compliance; deadline April 2025

  Stockholders' equity fell below $2M (Section 1003(a)(i)) and $4M (1003(a)(ii)) due to net losses.

• November 14, 2023, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Palatin Q1 FY2024 net loss narrows to $5.9M; Vyleesi revenue up 142% YoY

  Net loss per share $(0.48) vs $(0.86) YoY; Vyleesi net revenue $2.1M, +142% YoY.

• October 19, 2023, 7:59 PM ET earnings materiality 0.65 positive item 2.02item 8.01item 9.01 ◈ Earnings Releases

  Palatin prelim Q1: Vyleesi gross revenue $4.6M, net $2.1M, up 100% and 137% YoY

  Gross product revenue $4.6M (+11% qoq, +100% YoY); net product revenue $2.1M (+18% qoq, +137% YoY).

• October 13, 2023, 7:59 PM ET regulatory materiality 0.70 negative item 3.01item 8.01item 9.01 ◈ Listing & Compliance Notices

  Palatin receives NYSE American non-compliance notice for insufficient stockholders' equity

  Received NYSE American notice on Oct 10, 2023; stockholders' equity below $2M and $4M thresholds.

• September 28, 2023, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Palatin reports FY2023 net loss $27.5M; Vyleesi net revenue up 298%; PL9643 fully enrolled

  Net loss of $27.5M ($2.53 diluted EPS) for FY2023 vs $36.2M loss ($3.79 EPS) in FY2022.

• September 7, 2023, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Palatin completes enrollment in Phase 3 dry eye study (PL9643); 570 patients enrolled, topline expected Q4 2023

  PL9643 MELODY-1 Phase 3 study enrolled 570 patients with moderate-to-severe dry eye disease.

• August 10, 2023, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Palatin initiates Phase 2 study of bremelanotide/PDE5i combo for ED non-responders

  Approximately 30–40% of ED patients do not respond to PDE5i monotherapy.

• August 8, 2023, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Palatin: Fosun reports first Vyleesi sale in China; Kwangdong completes Phase 3 enrollment

  Fosun dispensed first Vyleesi prescription in Hainan Province, China.

• July 11, 2023, 7:59 PM ET earnings materiality 0.75 positive item 8.01item 9.01

  Palatin prelim Q4 Vyleesi net revenue $1.7M, up 122% YoY; prescriptions +89% YoY

  Gross product revenue $4.1M, up 20% QoQ and 78% YoY.

• May 16, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Palatin Q3 FY2023 net loss $7.1M; Vyleesi revenue up 453% YoY; Phase 3 dry eye data positive

  Net loss $7.1M ($0.63/share) vs $7.6M ($0.80) prior year; operating expenses $8.5M.

• April 27, 2023, 7:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Palatin reports positive initial Phase 3 data for PL9643 dry eye drug at ARVO

  PL9643 showed statistically significant improvement on multiple sign and symptom endpoints in Phase 2 and Phase 3 lead-in data.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

15 positive 11 negative 24 neutral

source · PTN on sec.gov